ATE451364T1 - Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate - Google Patents

Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate

Info

Publication number
ATE451364T1
ATE451364T1 AT05707610T AT05707610T ATE451364T1 AT E451364 T1 ATE451364 T1 AT E451364T1 AT 05707610 T AT05707610 T AT 05707610T AT 05707610 T AT05707610 T AT 05707610T AT E451364 T1 ATE451364 T1 AT E451364T1
Authority
AT
Austria
Prior art keywords
dopamine
modulators
receptor
derivatives suitable
derivatives
Prior art date
Application number
AT05707610T
Other languages
English (en)
Inventor
Luca Arista
Giorgio Bonanomi
Anna Maria Capelli
Federica Damiani
Fabio Romano Di
Gabriella Gentile
Dieter Hamprecht
Fabrizio Micheli
Luca Tarsi
Giovanna Tedesco
Silvia Terreni
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE451364T1 publication Critical patent/ATE451364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05707610T 2004-02-23 2005-02-21 Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate ATE451364T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
PCT/EP2005/001940 WO2005080382A1 (en) 2004-02-23 2005-02-21 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
ATE451364T1 true ATE451364T1 (de) 2009-12-15

Family

ID=34890800

Family Applications (3)

Application Number Title Priority Date Filing Date
AT05707610T ATE451364T1 (de) 2004-02-23 2005-02-21 Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AT08169935T ATE542816T1 (de) 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
AT08169934T ATE520686T1 (de) 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT08169935T ATE542816T1 (de) 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
AT08169934T ATE520686T1 (de) 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Country Status (25)

Country Link
US (3) US7855298B2 (de)
EP (3) EP2060570B1 (de)
JP (1) JP4960217B2 (de)
KR (1) KR101143718B1 (de)
CN (1) CN1946714B (de)
AR (1) AR047890A1 (de)
AT (3) ATE451364T1 (de)
AU (2) AU2005215918C1 (de)
BR (1) BRPI0507945A (de)
CA (1) CA2557115C (de)
CY (3) CY1109854T1 (de)
DE (1) DE602005018190D1 (de)
DK (3) DK2070922T3 (de)
ES (2) ES2380990T3 (de)
HR (3) HRP20100114T1 (de)
IL (1) IL177184A0 (de)
MA (1) MA28438B1 (de)
NO (1) NO20064309L (de)
PE (1) PE20051173A1 (de)
PL (3) PL1745040T3 (de)
PT (3) PT2060570E (de)
RU (1) RU2434011C2 (de)
SI (3) SI1745040T1 (de)
TW (1) TW200538113A (de)
WO (1) WO2005080382A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
JP5068747B2 (ja) 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EA200870404A1 (ru) * 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
ATE498619T1 (de) * 2006-04-03 2011-03-15 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
EP2481737A1 (de) 2008-06-24 2012-08-01 Merck Sharp & Dohme Corp. Biokatalytische Verfahren zur Herstellung substantiell stereomer reinkondensierter, bicyclischer Prolinverbindungen
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2012102094A (ru) * 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3068226A4 (de) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Neuartige verfahren
ES2821896T3 (es) * 2015-08-05 2021-04-28 Indivior Uk Ltd Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
IL298957A (en) 2020-06-22 2023-02-01 Corcept Therapeutics Inc Quaternary indazole glucocorticoid receptor antagonists
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR20240125035A (ko) 2021-12-21 2024-08-19 코어셉트 쎄라퓨틱스 인코포레이티드 이환 인다졸 글루코코르티코이드 수용체 길항제
MX2024007590A (es) 2021-12-21 2024-08-20 Corcept Therapeutics Inc Antagonistas piperazino indazólicos del receptor de glucocorticoides.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
AR035369A1 (es) 2000-11-14 2004-05-12 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EA200870404A1 (ru) 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
HRP20120281T1 (hr) 2012-04-30
PL2060570T3 (pl) 2012-06-29
US7855298B2 (en) 2010-12-21
EP1745040A1 (de) 2007-01-24
KR20060127991A (ko) 2006-12-13
JP4960217B2 (ja) 2012-06-27
PT2060570E (pt) 2012-05-07
CA2557115C (en) 2012-10-02
PE20051173A1 (es) 2006-02-14
EP2060570A2 (de) 2009-05-20
AR047890A1 (es) 2006-03-01
AU2009212887A1 (en) 2009-09-24
DE602005018190D1 (de) 2010-01-21
AU2005215918C1 (en) 2010-01-21
DK2070922T3 (da) 2011-11-28
US20100152195A1 (en) 2010-06-17
PT1745040E (pt) 2010-03-08
PT2070922E (pt) 2011-11-24
EP2070922A1 (de) 2009-06-17
ES2380990T3 (es) 2012-05-22
EP2060570A3 (de) 2009-06-03
RU2006133909A (ru) 2008-03-27
BRPI0507945A (pt) 2007-07-24
EP2070922B1 (de) 2011-08-17
US20070142438A1 (en) 2007-06-21
DK2060570T3 (da) 2012-04-30
US20100160336A1 (en) 2010-06-24
TW200538113A (en) 2005-12-01
SI2060570T1 (sl) 2012-05-31
PL1745040T3 (pl) 2010-05-31
IL177184A0 (en) 2006-12-10
US8283474B2 (en) 2012-10-09
JP2007523208A (ja) 2007-08-16
MA28438B1 (fr) 2007-02-01
AU2005215918B2 (en) 2009-06-11
EP1745040B1 (de) 2009-12-09
NO20064309L (no) 2006-11-23
HK1103016A1 (en) 2007-12-14
US8263782B2 (en) 2012-09-11
CN1946714A (zh) 2007-04-11
KR101143718B1 (ko) 2012-07-05
ES2337590T3 (es) 2010-04-27
SI1745040T1 (sl) 2010-04-30
RU2434011C2 (ru) 2011-11-20
ATE520686T1 (de) 2011-09-15
ATE542816T1 (de) 2012-02-15
AU2005215918A1 (en) 2005-09-01
HRP20100114T1 (hr) 2010-04-30
CY1113029T1 (el) 2016-04-13
CN1946714B (zh) 2011-06-15
CA2557115A1 (en) 2005-09-01
EP2060570B1 (de) 2012-01-25
CY1112011T1 (el) 2015-11-04
WO2005080382A1 (en) 2005-09-01
DK1745040T3 (da) 2010-04-12
EP1745040B9 (de) 2010-06-02
SI2070922T1 (sl) 2011-12-30
CY1109854T1 (el) 2014-09-10
PL2070922T3 (pl) 2012-01-31
HRP20110781T1 (hr) 2011-11-30

Similar Documents

Publication Publication Date Title
DE602005018190D1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
CY2017008I2 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
FR2895868B1 (fr) Dispositif de casque d'ecoute
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE487691T1 (de) Acetylenderivate
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ES1065052Y (es) Dispositivo para el suministro de perfume
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
ATE496049T1 (de) Als monoamin wiederaufnahmehemmer geeignete 8- azabicycloä3.2.1üoctanderivate
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DE112005002826A5 (de) Ausgleichseinheit
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
FI20040569A0 (fi) Tuloilmalaite
ATE538121T1 (de) 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
DE602006005006D1 (de) Als modulatoren des glucocorticoidrezeptors geeignete nichtsteroidale verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1745040

Country of ref document: EP